The Experts below are selected from a list of 1548 Experts worldwide ranked by ideXlab platform

Amnon Brzezinski - One of the best experts on this subject based on the ideXlab platform.

  • Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women
    Fertility and sterility, 1995
    Co-Authors: Benjamin Reubinoff, Ahuva Grubstein, Dror Meirow, Elliot M. Berry, Joseph G. Schenker, Amnon Brzezinski
    Abstract:

    Objective To determine prospectively whether the use of low-dose estrogen oral contraceptives (OC) is associated with changes in weight, body composition, or fat distribution. Design Anthropometric measurements were performed in 49 healthy young (16 to 21 years old) women before commencement of OC use (30 μg ethinyl estradiol [EE 2 ] plus 75 μg gestodene) and after three and six treatment cycles. Thirty one age- and weight-matched women who were not using OC served as controls. Setting Outpatient gynecological clinic of Hadassah Medical Center, a tertiary level hospital, and the "Shilo" voluntary service for the prevention of unwanted pregnancy. Main Outcome Measures Anthropometric measurements included body mass index (BMI), waist-to-Hip Girth ratio, and body composition (the percentage of body fat and water), estimated by mean of infrared interactance. Results In the group of OC users, baseline BMI, percent fat, percent water, and waist-to-Hip Girth ratio were 21.1±0.32 (kg/m 2 ), 23.8%±0.63%, 57.4%±0.39%, and 0.73±0.01, respectively, and did not change significantly after six cycles (20.6±0.41 [kg/m 2 ], 23.9%±0.57%, 58.1%±0. 49%, and 0.72±0.03, respectively). These measurements were not significantly different when compared with the nonusers. Fifteen OC users (30.6%) gained weight (>0.5 kg). Weight gain was due to a significant accumulation of fat (from 22.5%±1.1% to 25.6%±0.74%), whereas the percentage of body water remained stable. The waist-to-Hip Girth ratio also was not changed significantly. Similarly, 11 nonusers (35.4%) gained weight because of similar nonabdominal fat accumulation. Ten OC users (20.4%) lost weight (57kg±1.51 to 55.4±1.47 [mean±SEM]) and 6 nonusers (19.3%) also lost weight (59kg±1.42 to 57.3±1.92). In both groups the loss of weight was not associated with significant change in body composition. Conclusions The use of low-dose OC (EE 2 plus gestodene) was not associated with overall impact on weight, body composition, or fat distribution. However, when weight gain did occur during OC use, it was due to increase in body fat and not in volume of body water, and it was not associated with changes in fat distribution.

  • Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study.
    Fertility and sterility, 1995
    Co-Authors: Benjamin Reubinoff, Joseph G. Schenker, Judith J. Wurtman, Natan Rojansky, Dorit Adler, Pnina Stein, Amnon Brzezinski
    Abstract:

    Objective To evaluate the effects of hormone replacement therapy (HRT) on body weight and composition, fat distribution, and food intake in women entering the climacteric. Design Prospective clinical study. Setting Outpatient menopause clinic at a tertiary medical center. Participants Sixty-three early postmenopausal women (44 to 54 years old) were prospectively studied for 1 year. They consisted of two groups: group A, 34 subjects who initiated continuous estrogen and progestin treatment (daily oral conjugated estrogen 0.625mg and medroxyprogesterone acetate 2.5mg), and group B, 29 women who refused hormonal therapy and served as controls. The age, menopausal status, initial anthropometric measurements (weight, body mass index [BMI], fat mass, and waist-to-Hip Girth ratio), and daily food intake (total caloric intake and food composition) were similar in both groups. Interventions Anthropometric measurements were performed before commencement of HRT use and after 12 months. Main Outcome Measures Anthropometric measurements included BMI, waist-to-Hip Girth ratio, and body composition (the percentage of body fat and water) estimated by means of infrared interactance. Daily food intake was also recorded. Results The body weight and fat mass increased significantly in both the treatment (73.22±2.01 [mean±SE] to 75.57±1.12 kg) and the control group (71.45±3.11 to 73.51±1.23 kg). However, a significant shift from gynoid to android fat distribution was observed only in the control group (waist-to-Hip ratio shifted from 0.80±0.01 to 0.85±0.01), whereas no significant change was observed in the treatment group (0.81±0.01 to 0.82±0.01). Caloric and macronutrient intake did not change in either group. Conclusions These results indicate that continuous daily estrogen and progestin replacement therapy neither prevents nor increases early postmenopausal weight gain and fat accumulation. However, it does minimize the shift from gynoid to android fat distribution.

Benjamin Reubinoff - One of the best experts on this subject based on the ideXlab platform.

  • Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women
    Fertility and sterility, 1995
    Co-Authors: Benjamin Reubinoff, Ahuva Grubstein, Dror Meirow, Elliot M. Berry, Joseph G. Schenker, Amnon Brzezinski
    Abstract:

    Objective To determine prospectively whether the use of low-dose estrogen oral contraceptives (OC) is associated with changes in weight, body composition, or fat distribution. Design Anthropometric measurements were performed in 49 healthy young (16 to 21 years old) women before commencement of OC use (30 μg ethinyl estradiol [EE 2 ] plus 75 μg gestodene) and after three and six treatment cycles. Thirty one age- and weight-matched women who were not using OC served as controls. Setting Outpatient gynecological clinic of Hadassah Medical Center, a tertiary level hospital, and the "Shilo" voluntary service for the prevention of unwanted pregnancy. Main Outcome Measures Anthropometric measurements included body mass index (BMI), waist-to-Hip Girth ratio, and body composition (the percentage of body fat and water), estimated by mean of infrared interactance. Results In the group of OC users, baseline BMI, percent fat, percent water, and waist-to-Hip Girth ratio were 21.1±0.32 (kg/m 2 ), 23.8%±0.63%, 57.4%±0.39%, and 0.73±0.01, respectively, and did not change significantly after six cycles (20.6±0.41 [kg/m 2 ], 23.9%±0.57%, 58.1%±0. 49%, and 0.72±0.03, respectively). These measurements were not significantly different when compared with the nonusers. Fifteen OC users (30.6%) gained weight (>0.5 kg). Weight gain was due to a significant accumulation of fat (from 22.5%±1.1% to 25.6%±0.74%), whereas the percentage of body water remained stable. The waist-to-Hip Girth ratio also was not changed significantly. Similarly, 11 nonusers (35.4%) gained weight because of similar nonabdominal fat accumulation. Ten OC users (20.4%) lost weight (57kg±1.51 to 55.4±1.47 [mean±SEM]) and 6 nonusers (19.3%) also lost weight (59kg±1.42 to 57.3±1.92). In both groups the loss of weight was not associated with significant change in body composition. Conclusions The use of low-dose OC (EE 2 plus gestodene) was not associated with overall impact on weight, body composition, or fat distribution. However, when weight gain did occur during OC use, it was due to increase in body fat and not in volume of body water, and it was not associated with changes in fat distribution.

  • Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study.
    Fertility and sterility, 1995
    Co-Authors: Benjamin Reubinoff, Joseph G. Schenker, Judith J. Wurtman, Natan Rojansky, Dorit Adler, Pnina Stein, Amnon Brzezinski
    Abstract:

    Objective To evaluate the effects of hormone replacement therapy (HRT) on body weight and composition, fat distribution, and food intake in women entering the climacteric. Design Prospective clinical study. Setting Outpatient menopause clinic at a tertiary medical center. Participants Sixty-three early postmenopausal women (44 to 54 years old) were prospectively studied for 1 year. They consisted of two groups: group A, 34 subjects who initiated continuous estrogen and progestin treatment (daily oral conjugated estrogen 0.625mg and medroxyprogesterone acetate 2.5mg), and group B, 29 women who refused hormonal therapy and served as controls. The age, menopausal status, initial anthropometric measurements (weight, body mass index [BMI], fat mass, and waist-to-Hip Girth ratio), and daily food intake (total caloric intake and food composition) were similar in both groups. Interventions Anthropometric measurements were performed before commencement of HRT use and after 12 months. Main Outcome Measures Anthropometric measurements included BMI, waist-to-Hip Girth ratio, and body composition (the percentage of body fat and water) estimated by means of infrared interactance. Daily food intake was also recorded. Results The body weight and fat mass increased significantly in both the treatment (73.22±2.01 [mean±SE] to 75.57±1.12 kg) and the control group (71.45±3.11 to 73.51±1.23 kg). However, a significant shift from gynoid to android fat distribution was observed only in the control group (waist-to-Hip ratio shifted from 0.80±0.01 to 0.85±0.01), whereas no significant change was observed in the treatment group (0.81±0.01 to 0.82±0.01). Caloric and macronutrient intake did not change in either group. Conclusions These results indicate that continuous daily estrogen and progestin replacement therapy neither prevents nor increases early postmenopausal weight gain and fat accumulation. However, it does minimize the shift from gynoid to android fat distribution.

Joseph G. Schenker - One of the best experts on this subject based on the ideXlab platform.

  • Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women
    Fertility and sterility, 1995
    Co-Authors: Benjamin Reubinoff, Ahuva Grubstein, Dror Meirow, Elliot M. Berry, Joseph G. Schenker, Amnon Brzezinski
    Abstract:

    Objective To determine prospectively whether the use of low-dose estrogen oral contraceptives (OC) is associated with changes in weight, body composition, or fat distribution. Design Anthropometric measurements were performed in 49 healthy young (16 to 21 years old) women before commencement of OC use (30 μg ethinyl estradiol [EE 2 ] plus 75 μg gestodene) and after three and six treatment cycles. Thirty one age- and weight-matched women who were not using OC served as controls. Setting Outpatient gynecological clinic of Hadassah Medical Center, a tertiary level hospital, and the "Shilo" voluntary service for the prevention of unwanted pregnancy. Main Outcome Measures Anthropometric measurements included body mass index (BMI), waist-to-Hip Girth ratio, and body composition (the percentage of body fat and water), estimated by mean of infrared interactance. Results In the group of OC users, baseline BMI, percent fat, percent water, and waist-to-Hip Girth ratio were 21.1±0.32 (kg/m 2 ), 23.8%±0.63%, 57.4%±0.39%, and 0.73±0.01, respectively, and did not change significantly after six cycles (20.6±0.41 [kg/m 2 ], 23.9%±0.57%, 58.1%±0. 49%, and 0.72±0.03, respectively). These measurements were not significantly different when compared with the nonusers. Fifteen OC users (30.6%) gained weight (>0.5 kg). Weight gain was due to a significant accumulation of fat (from 22.5%±1.1% to 25.6%±0.74%), whereas the percentage of body water remained stable. The waist-to-Hip Girth ratio also was not changed significantly. Similarly, 11 nonusers (35.4%) gained weight because of similar nonabdominal fat accumulation. Ten OC users (20.4%) lost weight (57kg±1.51 to 55.4±1.47 [mean±SEM]) and 6 nonusers (19.3%) also lost weight (59kg±1.42 to 57.3±1.92). In both groups the loss of weight was not associated with significant change in body composition. Conclusions The use of low-dose OC (EE 2 plus gestodene) was not associated with overall impact on weight, body composition, or fat distribution. However, when weight gain did occur during OC use, it was due to increase in body fat and not in volume of body water, and it was not associated with changes in fat distribution.

  • Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study.
    Fertility and sterility, 1995
    Co-Authors: Benjamin Reubinoff, Joseph G. Schenker, Judith J. Wurtman, Natan Rojansky, Dorit Adler, Pnina Stein, Amnon Brzezinski
    Abstract:

    Objective To evaluate the effects of hormone replacement therapy (HRT) on body weight and composition, fat distribution, and food intake in women entering the climacteric. Design Prospective clinical study. Setting Outpatient menopause clinic at a tertiary medical center. Participants Sixty-three early postmenopausal women (44 to 54 years old) were prospectively studied for 1 year. They consisted of two groups: group A, 34 subjects who initiated continuous estrogen and progestin treatment (daily oral conjugated estrogen 0.625mg and medroxyprogesterone acetate 2.5mg), and group B, 29 women who refused hormonal therapy and served as controls. The age, menopausal status, initial anthropometric measurements (weight, body mass index [BMI], fat mass, and waist-to-Hip Girth ratio), and daily food intake (total caloric intake and food composition) were similar in both groups. Interventions Anthropometric measurements were performed before commencement of HRT use and after 12 months. Main Outcome Measures Anthropometric measurements included BMI, waist-to-Hip Girth ratio, and body composition (the percentage of body fat and water) estimated by means of infrared interactance. Daily food intake was also recorded. Results The body weight and fat mass increased significantly in both the treatment (73.22±2.01 [mean±SE] to 75.57±1.12 kg) and the control group (71.45±3.11 to 73.51±1.23 kg). However, a significant shift from gynoid to android fat distribution was observed only in the control group (waist-to-Hip ratio shifted from 0.80±0.01 to 0.85±0.01), whereas no significant change was observed in the treatment group (0.81±0.01 to 0.82±0.01). Caloric and macronutrient intake did not change in either group. Conclusions These results indicate that continuous daily estrogen and progestin replacement therapy neither prevents nor increases early postmenopausal weight gain and fat accumulation. However, it does minimize the shift from gynoid to android fat distribution.

Arny A Ferrando - One of the best experts on this subject based on the ideXlab platform.

  • eight weeks of supplementation with a multi ingredient weight loss product enhances body composition reduces Hip and waist Girth and increases energy levels in overweight men and women
    Journal of The International Society of Sports Nutrition, 2012
    Co-Authors: Hector L Lopez, Tim N Ziegenfuss, Jennifer E Hofheins, S M Habowski, Shawn M Arent, Joseph P Weir, Arny A Ferrando
    Abstract:

    Numerous natural products are marketed and sold claiming to decrease body weight and fat, but few undergo finished product-specific research demonstrating their safety and efficacy. To determine the safety and efficacy of a multi-ingredient supplement containing primarily raspberry ketone, caffeine, capsaicin, garlic, ginger and Citrus aurantium (Prograde Metabolism™ [METABO]) as an adjunct to an eight-week weight loss program. Using a randomized, placebo-controlled, double-blind design, 70 obese but otherwise healthy subjects were randomly assigned to METABO or a placebo and underwent 8 weeks of daily supplementation, a calorie restricted diet, and exercise training. Subjects were tested for changes in body composition, serum adipocytokines (adiponectin, resistin, leptin, TNF-α, IL-6) and markers of health including heart rate and blood pressure. Of the 45 subjects who completed the study, significant differences were observed in: body weight (METABO -2.0% vs. placebo -0.5%, P < 0.01), fat mass (METABO -7.8 vs. placebo -2.8%, P < 0.001), lean mass (METABO +3.4% vs. placebo +0.8%, P < 0.03), waist Girth (METABO -2.0% vs. placebo -0.2%, P < 0.0007), Hip Girth (METABO -1.7% vs. placebo -0.4%, P < 0.003), and energy levels per anchored visual analogue scale (VAS) (METABO +29.3% vs. placebo +5.1%, P < 0.04). During the first 4 weeks, effects/trends for maintaining elevated serum leptin (P < 0.03) and decreased serum resistin (P < 0.08) in the METABO group vs. placebo were also observed. No changes in systemic hemodynamics, clinical blood chemistries, adverse events, or dietary intake were noted between groups. METABO administration is a safe and effective adjunct to an eight-week diet and exercise weight loss program by augmenting improvements in body composition, waist and Hip Girth. Adherence to the eight-week weight loss program also led to beneficial changes in body fat in placebo. Ongoing studies to confirm these results and clarify the mechanisms (i.e., biochemical and neuroendocrine mediators) by which METABO exerts the observed salutary effects are being conducted.

Liu Xing-hui - One of the best experts on this subject based on the ideXlab platform.

  • The RelationsHip of the Serum Resistin Level and Hemorheological Indices in Patients with Metabolic Syndrome
    Preventive Medicine Tribune, 2010
    Co-Authors: Liu Xing-hui
    Abstract:

    [Objective] To investigate the relationsHip of the serum resistin level and hemorheological indices in patients with metabolic syndrome(MS).[Methods]In 2004 and 2010,60 MS patients were divided into obesity group and non-obesity group according to BMI,28 age-matched normal persons were chosen as controls.Height,weight,waist circumstance,Hip Girth,blood pressure,blood glucose,blood lipid and hemorheological indices in all the patients and controls were measured and compared.[Results]The BMI,waist circumstance,Hip Girth,waist to Hip ratio(WHR),systolic pressure,diastolic pressure in the obesity group and non-obesity group of MS were significantly higher than those of the control group(P0.01).The BMI,waist circumstance,Hip Girth in the obesity group of MS were significantly higher than the non-obesity group of MS(P0.01).The serum resistin level on an empty stomach in the obesity group and non-obesity group of MS was higher than those of the control group(P0.05 or P0.01).The FBG,TC,TG,C-HDL,whole blood viscosity at high shear rate,whole blood viscosity at middle shear rate,whole blood viscosity at low shear rate,Plasma Viscosity,HCT,ARBC,IR in the two groups of MS were significantly higher than those of the control group(P0.01).[Conclusion]The increase of serum resistin level in MS patients may causes hemorheological changes.